Blood test may guide lung cancer treatment
NCT ID NCT02551211
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if immune cells in the blood match those inside lung tumors. Researchers hoped to find a simple blood test that could help doctors decide which patients might respond to immunotherapy. The study planned to enroll 22 people with early-stage lung cancer who were having surgery, but it was terminated early.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test that helps doctors decide which lung cancer patients might benefit from immunotherapy.
- What could go wrong
- This was a small, early study that was terminated early, so results may be incomplete. The findings may not apply to all lung cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
22 people
The number who actually took part.
- Started
-
Dec 2016
- Finished
-
Feb 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women over 18 years of age * Histologically- or cytologically- confirmed non-small cell lung cancer diagnostic * Stage I, II or IIIA NSCLC (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology). Staging must have included an abdominal and thoracic CTscan, a CTscan or MRI of the brain and a 18FDG PETscan * Subjects for whom a surgical resection is indicated * Signed written informed consent Exclusion Criteria: * \- previous, ongoing or planned neo-adjuvant treatment (chemotherapy, targeted therapy, immunotherapy or radiotherapy) * contraindications to general anesthesia * contraindication to the planned surgical resection * history of immunosuppressive disorder * known history of testing positive for human immunodeficiency virus * subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 30 days of randomization. * clinical suspicion of active infection (either acute or chronic) * severe (hemoglobin \< 8.0 g/dL) or symptomatic anemia * women of childbearing potential must have a negative urine pregnancy test * women must not be breastfeeding * prisoners or subjects who are involuntarily incarcerated * subjects under guardianship
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Resectable non-small lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rouen University Hospital
Rouen, France